PRECISION MEDICINE
Personalized Medicine Genetic Testing in Miami

Ready to get started or want to learn more? Fill out the form below.

    Personalized Genetic Testing in Miami provides the invaluable service of personalized genetic medicine testing to physicians and patients throughout the U.S.

     

    Thousands of Tests Performed

    Providing doctors with the information needed to determine the best medicines and treatments for each of their patients.

    20+ Years Experience

    Experience in biotechnology, pharmaceutical, hematology, flow cytometry, clinical molecular biology, immunology, and chemistry industries.

    Fast 5-Day Turnaround

    Using the latest technologies from the leaders in the industry, our process is 3 times faster than competitor’s analysis methods.

    Accurate Reporting

    Through Coriell Institute, backed by over 60 years of research experience providing the quality control required for validation in pharmacogenetics testing.

    Personalized Genetic Testing provides a wide range of personalized medicine genetic testing and pharmacogenomics testing. Examples of what patients can be tested for include:

     

    CARDIOVASCULAR DRUGS

    SOMATIC MUTATIONS

    ONCOLOGY MEDICATIONS

    PSYCHOTROPIC MEDICATIONS

    PAIN MANAGEMENT DRUGS

    DIABETES MEDICATIONS

    APOE GENE

    Determine Risk of Vascular Disease

    FACTOR V LEIDEN

    Determine Risk of Thrombosis

    MTHFR

    Determine risk factor for cardiovascular disease

    COMT

    Enzyme that degrades dopamine and norepinephrine

    PGT’s genetic medication testing supports doctors in determining the appropriate medications and doses that are best suited for a patient’s genetic profile.

    PGT Comprehensive Panel provides genetic results for:
    CYP2D6  CYP2D6 testing has been revealed to have an important outcome on the body’s ability to metabolize opioids such as Oxycodone, Codeine, and Tramadol.
    CYP2C19 Has been connected to the metabolism of Carisoprodol, a skeletal muscle relaxant. Genetic testing medication assists in determining the appropriate personalised medicine therapies.
    CYP2C9 CYP2C9 customized medicine testing is done for those taking the most common pain medications as it is responsible for the metabolism of most NSAID pain medications.
    CYP3A4/A5 Medication genetic testing is done for those taking narcotics for severe pain as it affects the body’s ability to metabolize Fentanyl. Genetic testing medication metabolism can assist in prescribing the right dose of these type of medications.
    CYP1A2 Is primarily responsible for clozapine metabolism. The genetic studies of clozapine drug response are supported by the identification of multiple functional variants in CYP1A2,  with well-defined effects on clozapine metabolism.

    SLCO1B1

    An influx transporter that moves drugs into cells. Variations may affect the blood levels of drugs that are substrates for this transporter. Testing can be done for those that take common classes of medications such as Statins as these are mostly affected. Genetic lab testing can help to determine interactions and individual medicine treatment.

    VKORC1

    Made primarily in the liver, the gene provides instructions for making a vitamin K epoxide reductase enzyme.

    CYP2B6

    Responsible for the metabolism of the most active metabolite of bupropion. Personal medicine gene testing can help determine appropriate doses of these types of medication.

    COMT

    An enzyme that degrades dopamine and norepinephrine, primarily in the prefrontal cortex of the brain a pharmacodynamic gen which has been implicated in the therapeutic response of patients taking stimulant medications (amphetamines) and some antipsychotics.

    F2/Factor II

    Prothrombin deficiency, thus creating the potential of a hypercoagulable state.

    F5/Factor V Leiden

    Inherited Thrombophilia. Factor V Leiden mutation is the greatest common inherited predisposition for hypercoagulability.  People with Factor V Leiden mutation with thrombophilia have higher than average risk of developing a blood clot called a deep venosus thrombosis (DVT).

    MTHFR

    A decrease in the function or amount of MTHFR causes increased blood levels of homocysteine. Increased homocysteine blood concentrations are associated with an increased risk for cardiovascular disease including venous thrombosis, atherosclerosis, stroke, and peripheral artery disease.

    OPRM1

    Has been associated with the therapeutic response of patients taking opioid medications. Customized medical testing for medication effectiveness can help determine proper dosing.

    ANKK1

    ANKK1 testing is used to determine risk factors for addictive disorders, with obesity and with the performance of executive functions. Gene testing can help to determine customized medical treatment.

    APOE

    People who carry APOE have an increased chance of developing atherosclerosis, and to greatly increase the risk of a rare condition called hyperlipoproteinemia type III.  Hyperlipoproteinemia type III is characterized by increased blood levels of cholesterol, certain fats called triglycerides, and molecules called beta-very low-density lipoproteins (beta-VLDLs), which carry cholesterol and lipoproteins in the bloodstream.